The Biospecimen Core of the Center for Mentoring Translational Cancer Research in Oklahoma will support promising junior investigators and other researchers in the Peggy and Charles Stephenson Oklahoma Cancer Center with provision and management of quality biospecimens. The Core will accomplish three aims: 1) Provide annotated human biospecimens, including blood and tissue components;2) Aid in the design and implementation of prospective specimen collection protocols and of histologic and molecular analyses of specimens;and 3) Construct tissue microarrays tailored to individual and collaborative research projects. The accomplishment of these aims will enhance and facilitate translational research on a variety of cancers. In particular, verifying the quality of biospecimens will help to ensure the validity of research results. In addition, providing clinicopathologic annotation of specimens will increase the relevance and significance of the various projects planned for this Center. Histologic quality control will be conducted by board-certified pathologists. Core data management services will provide standardized annotations using a secure database system. In select instances, the Core Director, Co-Director, and Pathology Consultants will assist investigators in the conception of prospective specimen collection protocols and specimen analysis, to minimize the effect of pre-analytic and analytic variables on study results. Finally, Core pathologists and staff will establish a tissue microarray construction service to allow high-throughput analysis of cancer specimens.

Agency
National Institute of Health (NIH)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-03
Application #
8723253
Study Section
Special Emphasis Panel (ZRR1)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Ramraj, Satish Kumar; Aravindan, Sheeja; Somasundaram, Dinesh Babu et al. (2016) Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. Oncotarget 7:18605-19
Zhang, Zhi; Subramaniam, Sabareesh; Kale, Justin et al. (2016) BH3-in-groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes. EMBO J 35:208-36
Huang, Qingling; Schneeberger, Valentina E; Luetteke, Noreen et al. (2016) Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther 15:2521-2529
Nguyen, Charles B; Kotturi, Hari; Waris, Gulam et al. (2016) (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res 76:4887-96
Corbin, Joshua M; Overcash, Ryan F; Wren, Jonathan D et al. (2016) Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer. Prostate 76:97-113
Srivastava, Akhil; Amreddy, Narsireddy; Babu, Anish et al. (2016) Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep 6:38541
Muralidharan, Ranganayaki; Babu, Anish; Amreddy, Narsireddy et al. (2016) Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology 14:47
Ha, Ji Hee; Ward, Jeremy D; Radhakrishnan, Rangasudhagar et al. (2016) Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gαi2, Src, and HIF1α signaling nexus. Oncotarget 7:37664-37679
Kim, Tae-Dong; Jin, Fang; Shin, Sook et al. (2016) Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest 126:706-20
Amreddy, Narsireddy; Muralidharan, Ranganayaki; Babu, Anish et al. (2015) Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine 10:6773-88

Showing the most recent 10 out of 38 publications